Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma

Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, Michael, Borad, Mitesh J, Bryce, Alan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613928/
https://www.ncbi.nlm.nih.gov/pubmed/28959512
http://dx.doi.org/10.7759/cureus.1517
_version_ 1783266341110677504
author Conroy, Michael
Borad, Mitesh J
Bryce, Alan H
author_facet Conroy, Michael
Borad, Mitesh J
Bryce, Alan H
author_sort Conroy, Michael
collection PubMed
description Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent.
format Online
Article
Text
id pubmed-5613928
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-56139282017-09-28 Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma Conroy, Michael Borad, Mitesh J Bryce, Alan H Cureus Oncology Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent. Cureus 2017-07-26 /pmc/articles/PMC5613928/ /pubmed/28959512 http://dx.doi.org/10.7759/cureus.1517 Text en Copyright © 2017, Conroy et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Conroy, Michael
Borad, Mitesh J
Bryce, Alan H
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title_full Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title_fullStr Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title_full_unstemmed Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title_short Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
title_sort hypoxia-activated alkylating agents in brca1-mutant ovarian serous carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613928/
https://www.ncbi.nlm.nih.gov/pubmed/28959512
http://dx.doi.org/10.7759/cureus.1517
work_keys_str_mv AT conroymichael hypoxiaactivatedalkylatingagentsinbrca1mutantovarianserouscarcinoma
AT boradmiteshj hypoxiaactivatedalkylatingagentsinbrca1mutantovarianserouscarcinoma
AT brycealanh hypoxiaactivatedalkylatingagentsinbrca1mutantovarianserouscarcinoma

Ejemplares similares